PARIS, France—Percutaneous edge-to-edge repair with a clip device appears to offer some hope for patients with tricuspid regurgitation, according to new results from the TRILUMINATE study. At 30 days, ...

LONDON, England—Results from several small and preliminary studies testing a range of devices for tricuspid regurgitation (TR) hint that percutaneous therapies are making progress for what’s long been ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN FRANCISCO -- ...

Atrium Health Sanger Heart & Vascular Institute cardiology team perform surgery on a patient with heart valve disease, using a newly, FDA-approved clip device. The device gives patients diagnosed with ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Atrium Health Sanger Heart & Vascular Institute has ...

A team of interventional cardiologists from Henry Ford Health's Center for Structural Heart Disease recently became the first in the United States and the Western Hemisphere to repair a heart valve ...

IOWA CITY, Iowa (KCRG) - About 5% of Americans have a specific heart disease called tricuspid regurgitation - it relates to one of the heart valves. “Tricuspid regurgitation is when that valve becomes ...

The Food and Drug Administration approved a new device from Abbott meant to treat tricuspid heart valve disease — an expected decision after an outside advisory panel voted that the device’s benefits ...

PHOENIX -- Tricuspid regurgitation (TR) at baseline was linked to poorer outcomes after percutaneous mitral valve repair and didn't improve for most patients afterward, two registry studies showed.

U.S. patients suffering from a leaky tricuspid valve, or tricuspid regurgitation (TR), have more treatment options than ever before, thanks to two significant FDA approvals. FDA has approved Abbott’s ...